Autolus Therapeutics Aktie - AUTL

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

2,07

Gebot

2,05

Fragen

2,09

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Marktkapitalisierung

550,872M

Handelsende

2,07

Handelsbeginn

Letzte Trade

2.0509

Letzter Handelszeitpunkt

14:00:00

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

266.121.689

Dividendenrendite

Kurs-Gewinn-Verhältnis

-2,64

Gewinn pro Aktie (EPS)

-0,78

Erlöse

1,7M

Nettogewinn

-208,38M

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.autolus.com

Hauptsitz

London, Gbr

Gegründet

Autolus Therapeutics PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AUTL. The last closing price for Autolus Therapeutics was US$2,07. Over the last year, Autolus Therapeutics shares have traded in a share price range of US$ 0,00 to US$ 0,00.

Autolus Therapeutics currently has 266.121.689 shares in issue. The market capitalisation of Autolus Therapeutics is US$550,87 million. Autolus Therapeutics has a price to earnings ratio (PE ratio) of -2.64.

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

AUTL - Frequently Asked Questions (FAQ)

What is the current Autolus Therapeutics share price?

The current share price of Autolus Therapeutics is US$ 2,07

How many Autolus Therapeutics shares are in issue?

Autolus Therapeutics has 266.121.689 shares in issue

What is the market cap of Autolus Therapeutics?

The market capitalisation of Autolus Therapeutics is USD 550,87M

What is the 1 year trading range for Autolus Therapeutics share price?

Autolus Therapeutics has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of Autolus Therapeutics?

The price to earnings ratio of Autolus Therapeutics is -2,64

What is the cash to sales ratio of Autolus Therapeutics?

The cash to sales ratio of Autolus Therapeutics is 323,44

What is the reporting currency for Autolus Therapeutics?

Autolus Therapeutics reports financial results in USD

What is the latest annual turnover for Autolus Therapeutics?

The latest annual turnover of Autolus Therapeutics is USD 1,7M

What is the latest annual profit for Autolus Therapeutics?

The latest annual profit of Autolus Therapeutics is USD -208,38M

What is the registered address of Autolus Therapeutics?

The registered address for Autolus Therapeutics is 191 WOOD LANE, LONDON, W12 7FP

What is the Autolus Therapeutics website address?

The website address for Autolus Therapeutics is www.autolus.com

Which industry sector does Autolus Therapeutics operate in?

Autolus Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SUNESUNation Energy Inc	US$ 0,4944 (179,16%)	180,74M
BTOGBit Origin Ltd	US$ 0,4809 (71,75%)	14,53M
HFBLHome Federal Bancorp Inc of Louisiana	US$ 19,85 (53,88%)	5
BBGIBeasley Broadcast Group Inc	US$ 9,99 (53,46%)	37
VTVTvTv Therapeutics Inc	US$ 25,00 (49,88%)	4
SYRESpyre Therapeutics Inc	US$ 13,01 (-36,54%)	70
LUNRIntuitive Machines Inc	US$ 7,20 (-36,06%)	4,41M
ACXPAcurx Pharmaceuticals Inc	US$ 0,432 (-33,74%)	83,07k
PROVProvident Financial Holdings Inc	US$ 11,20 (-24,78%)	18
USCBUSCB Financial Holdings Inc	US$ 14,20 (-20,89%)	12
SUNESUNation Energy Inc	US$ 0,4944 (179,16%)	180,74M
FAMIFarmmi Inc	US$ 0,31 (35,61%)	44,69M
PSTVPlus Therapeutics Inc	US$ 1,94 (34,72%)	29,15M
CTMXCytomX Therapeutics Inc	US$ 0,7213 (16,85%)	25,03M
ICONIcon Energy Corporation	US$ 0,1755 (21,03%)	24,65M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Autolus Therapeutics PLC (AUTL) Börsenkurse

Autolus Therapeutics PLC (AUTL)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Autolus Therapeutics PLC

AUTL Neueste Nachrichten

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Autolus Therapeutics Provides Business Updates and 2025 Overview

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Autolus Therapeutics Provides Business Updates and 2025 Overview

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

AUTL - Frequently Asked Questions (FAQ)

Beweger

AUTL Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR